Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to __________ Commission file number 001-38623 PAYSIGN, INC. (Former name, former address and former fiscal year, if changed since last rep ...

Financial Data and Key Metrics Changes - Total net revenue for Q2 2021 was $6.7 million, a year-over-year increase of 3.2% [7] - Gross margin for the quarter was 47.4%, aided by the end of one pharmaceutical program [17] - Net loss for the quarter was $932,000, with adjusted EBITDA at $219,000, indicating near breakeven performance [18] - Restricted cash grew to $65.8 million during the quarter [18] - Full year revenue guidance is expected to be in the range of $29 million to $32 million, reflecting growth of 20% to 32% [26] Business Line Data and Key Metrics Changes - Plasma revenue accounted for $5.9 million or 89% of total revenues, with a year-over-year increase of $1.4 million [17][19] - Pharma revenue decreased to $641,000, down $1.1 million compared to Q2 2020, primarily due to program terminations [21] - Average revenue per month per plasma center was $5,633, with a potential increase to $6,138 if excluding April [19] - The company onboarded 13 additional plasma centers, bringing the total to 356 [10] Market Data and Key Metrics Changes - Total gross funds loaded increased by 34.7% year-over-year, while it decreased by 10.9% from the previous quarter due to seasonality [8] - Purchase volume increased by 44.5% compared to the year-ago period [18] Company Strategy and Development Direction - The company is focusing on diversifying its business and investing for long-term growth, particularly in the patient affordability space [11] - New copay programs are being launched, with five additional programs expected to launch by the end of 2021 [11][22] - The leadership team has been strengthened with new appointments in key positions [12][13] Management's Comments on Operating Environment and Future Outlook - Management noted improving trends in financial results as pandemic-related stimulus measures ended, with expectations for continued improvement [14] - The outlook presumes no re-entry into lockdowns and a recovery in the plasma business as unemployment subsidies end [27] Other Important Information - The company exited the quarter with $6.6 million in unrestricted cash and zero debt [25] - Operating expenses for the full year are expected to increase modestly to $18 million to $18.5 million [27] Q&A Session Summary - No specific questions or answers were documented in the provided content, indicating a conclusion to the call without detailed Q&A interactions [29][30]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to __________ Commission file number 001-38623 PAYSIGN, INC. (Exact name of registrant as specified in its charter) (State or other jurisd ...

PaySign, Inc. (NASDAQ:PAYS) Q1 2021 Earnings Conference Call May 11, 2021 5:00 PM ET Company Participants Mark Newcomer - Co-Founder and Chief Executive Officer Jeff Baker - Chief Financial Officer Conference Call Participants Jon Hickman - Ladenburg Thalmann Michael Diana - Maxim Group Operator Hello, and welcome to the PaySign’s First Quarter 2021 Conference Call and Webcast. At this time, all participants are in a listen-only mode. [Operator Instructions] A question-and-answer session will follow the for ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 o TRANSITION PURSUANT TO UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File Number 001-38623 PAYSIGN, INC. (Exact name of registrant as specified in its charter) Nevada 95-4550154 (State ...

PaySign, Inc. (NASDAQ:PAYS) Q4 2020 Earnings Conference Call March 25, 2021 5:00 PM ET Company Participants Mark Newcomer – Co-Founder and Chief Executive Officer Jeff Baker – Chief Financial Officer Conference Call Participants Peter Heckmann – Davidson Austin Moldow – Canaccord Genuity Mark Palmer – BTIG Jon Hickman – Ladenburg Thalmann Operator Hello, and welcome to the Paysign’s Fourth Quarter and Full Year 2020 Earnings Conference Call. At this time, all participants are in a listen-only mode. A questi ...

PaySign, Inc. (NASDAQ:PAYS) Q3 2020 Earnings Conference Call November 17, 2020 5:00 PM ET Company Participants Mark Newcomer - President and Chief Executive Officer Mark Attinger - Chief Financial Officer Conference Call Participants Austin Moldow - Canaccord Genuity Peter Heckmann - D.A. Davidson Michael Diana - Maxim Group Graham Hickman - Ladenburg Thalmann Operator Hello and welcome to the PaySign 2020 Third Quarter Earnings Conference Call. [Operator instructions] This presentation may include forward- ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to __________ Commission file number 001-38623 PAYSIGN, INC. Indicate by check mark whether the registrant (1) has filed all reports r ...

Table of Contents Form 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 For the quarterly period ended June 30, 2020 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to __________ Commission file number 001-38623 PAYSIGN, INC. (Registrant's telephone number, including area code) N/A (Former name, former ...

PaySign, Inc. (NASDAQ:PAYS) Q2 2020 Earnings Conference Call August 13, 2020 5:00 PM ET Company Participants Mark Newcomer - Co-founder, Vice Chairman, President and Chief Executive Officer Mark Attinger - Chief Financial Officer and Treasurer Matthew Turner - Vice President and Head of Patient Affordability Solutions Conference Call Participants Peter Heckmann - D.A. Davidson & Co. Austin Moldow - Canaccord Genuity LLC Mark Palmer - BTIG, LLC Jon Hickman - Ladenburg Thalmann & Co. Operator Hello, and welco ...